Comparison of two techniques used in routine care for the treatment of inflammatory macular oedema, subconjunctival triamcinolone injection and intravitreal dexamethasone implant: medical and economic importance of this randomized controlled trial

DiscussionThe results of this trial will have a real impact on public health if it is shown that a Kenacort retard ® (i.e. triamcinolone) injection costing just €2.84 and performed in the physician’s office (with no additional overhead costs) is at least as effective as the dexamethasone 700 μg implant (Ozurdex®; costing approximately €960 with the injection performed in a dedicated room), with no inc reased side effects.Trial registrationClinicalTrials.gov,NCT02556424. Registered on 22 September 2015.
Source: Trials - Category: Research Source Type: clinical trials